Real-World Strategies to Enhance the Palatability of Coformulated Sodium Phenylbutyrate and Taurursodiol for the Treatment of Amyotrophic Lateral Sclerosis


Nicole Shuckett, RD¹; Steven Wainwright, PhD²; Tracey Jason, PhD²; Jamie Timmons, MD³

¹Independent consultant, Toronto, Ontario, Canada; ²Amylyx Pharmaceuticals, Inc., Winnipeg, Manitoba, Canada; ³Amylyx Pharmaceuticals, Inc., Cambridge, MA, USA

BACKGROUND

- An oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol/ursodoxicoltaurine (PB and TURSO) is approved to treat amyotrophic lateral sclerosis (ALS) in adults in the United States¹ and approved with conditions to treat ALS in Canada²
- PB and TURSO is a powder administered orally or via feeding tube after suspension in room temperature water.^{1,2} PB and TURSO can have a bitter taste to some people living with ALS (PLWALS) who take it orally, which may compromise adherence and, consequently, treatment effectiveness
- The Canadian product monograph provides specific details around how PLWALS can reduce the bitter aftertaste (**Figure 1**)²

Figure 1. Methods for Reducing Bitter Aftertaste of PB and TURSO²



Per Canadian product monograph.² PB and TURSO, sodium phenylbutyrate and taurursodiol.

TASTE IN PLWALS

- PLWALS may have altered taste perception for a multitude of reasons, including degeneration of the solitary nuclei, impairment of the cranial nerves innervating the taste buds, medications, and genetics^{3,4}
- In particular, differential disease effects on the cranial nerves may preserve or potentiate output from gustatory cells located in the circumvallate papillae that perceive bitter taste^{4,5}
- Prior to marketing approval in Canada, PB and TURSO was available through the Health Canada Special Access Program (SAP). As of September 13, 2022, 272 PLWALS with a mean age of 63 years received PB and TURSO through the SAP

PB and TURSO is an investigational drug not approved for use pending regulatory review in the European Medicines Agency for the treatment of ALS.



Contact Info: Tracey Jason, PhD Tracey_Jason@amylyx.com


OBJECTIVE

as part of the PB and TURSO Canadian SAP

METHODS

RESULTS

- clinic nurses/coordinators (n=3), and a neurologist specializing in ALS care (n=1)
- Participant responses were transcribed, and data were analyzed to generate themes



HCP, health care practitioner; PLWALS, people living with amyotrophic lateral sclerosis.

- All PLWALS who responded (100%) reported using ≥ 1 of the coping strategies identified
- None of the PLWALS (0%) reported discontinuing treatment owing to taste
- For context, of the 217 Canadian PLWALS exposed to PB and TURSO treatment through the SAP, 8 (3.7%) cited bitter taste among their reasons for discontinuation

CONCLUSION

and potentially enhance the palatability of PB and TURSO

Acknowledgement

The authors wish to acknowledge Knowledge Translation Partners for their assistance with writing the abstract corresponding with this poster presentation.

Disclosures NS was consulted by Amylyx to conduct the interviews. SW, TJ, and JT are full-time employees of Amylyx.

Presented at the 21st Annual NEALS Meeting; November 1–3, 2022

• To explore real-world coping strategies of PLWALS and health care practitioners for potentially enhancing PB and TURSO palatability based on their experiences

• One registered dietitian conducted individual, semistructured qualitative interviews with PLWALS receiving PB and TURSO via oral administration (n=6), ALS

Multiple real-world coping strategies to mask the bitter taste of PB and TURSO were identified in addition to those recommended in the Canadian product monograph for PB and TURSO. Altogether, these strategies encompassed 3 themes (Table 1): Optimism and hope in chronic disease

- Medication administration techniques
- Taste-enhancing techniques

Table 1. Real-World Coping Strategies for Enhancing PB and TURSO Palatability

Optimism and Hope in Chronic Disease

- Feelings of hope help outweigh bitter taste of the therapy
- Ability to accept the taste and the potential positive impact of treatment on disease symptoms
- Taste buds have changed with the disease, so bitter taste is less of an issue
- Conversations (verbal/email) with HCPs about how to optimize medication palatability are very helpful with medication adherence

- Drir
- with
- Pince SUS
- Drin
- one

^aDenotes strategies that are not included in the Canadian product monograph. HCP, health care practitioner; PB and TURSO, sodium phenylbutyrate and taurursodiol.

Although further studies are needed to substantiate and enrich these preliminary results, these data suggest that a variety of strategies may be successfully applied in the real-world setting to manage taste expectations

References

1. RELYVRIO. Prescribing information. Amylyx Pharmaceuticals, Inc.; 2022. 2. ALBRIOZA. Product monograph. Amylyx Pharmaceuticals, Inc.; 2022. 3. Petzold GC, et al. J Neurol Neurosurg Psychiatry. 2003;74(5):687-688. 4. Pelletier CA, et al. Chemosens Percept. 2013;6:101-107. 5. Yanagisawa K, et al. *Physiol Behav.* 1998;63(3):329-335.



Medication Administration Techniques	Taste-Enhancing Techniques
 Mix medication with a milk frother^a Shake suspension in a mason jar^a Stir suspension with a spoon Drink suspension with a straw Pinch nose and drink suspension^a 	 After taking the suspension, try Nature's Wild Berry^a After taking the suspension, try chocolate pudding, chocolate, a banana, a boiled egg, salt-and- vinegar potato chips, crackers, cookies, applesauce, black coffee, yogurt, Listerine strips, or mouthwash After taking the suspension, brush teeth^a Avoid eating or drinking anything citrusy after taking the suspension, as that makes the taste more bitter
 Drink suspension in one gulp^a 	